Century Therapeutics (IPSC) Non-Current Deffered Revenue (2022 - 2024)

Century Therapeutics (IPSC) has 3 years of Non-Current Deffered Revenue data on file, last reported at $109.8 million in Q3 2024.

• Non-Current Deffered Revenue for Q3 2024 came in at $109.8 million, down 2.12% year-over-year; the trailing twelve-month figure through Sep 2024 was $109.8 million (down 2.12% YoY), and the FY2023 annual result was $111.4 million, changed 0.49% from the prior year.
• Non-Current Deffered Revenue was little changed at $109.8 million in Q3 2024 per IPSC's latest filing, from $109.8 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $115.8 million in Q1 2022 and troughed at $109.2 million in Q2 2023.
• A 3-year average of $111.2 million and a median of $110.8 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• On a YoY basis, Non-Current Deffered Revenue climbed as much as 1.09% in 2023 and fell as far as 5.17% in 2023.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $110.8 million in 2022, then increased by 0.49% to $111.4 million in 2023, then slipped by 1.45% to $109.8 million in 2024.
• Business Quant data shows IPSC's Non-Current Deffered Revenue at $109.8 million in Q3 2024, $109.8 million in Q2 2024, and $110.3 million in Q1 2024.